LBA-6: Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or bortezomib (DPd/DVd) in patients (Pts) with relapsed/refractory Multiple Myeloma (RRMM): R...

LBA-5: A hospital policy of tranexamic acid to reduce transfusion in major non-cardiac surgery: The TRACTION trial (ORLANDO, Dec. 9, 2025) –– When hospitals were randomly assigned to treat patients undergoing higher-risk non-cardiac surgery with tra...

LBA-3: Pirtobrutinib vs Bendamustine Plus Rituximab (BR) in Patients with CLL/SLL: First Results from a Randomized Phase III Study Examining a Non-Covalent BTK Inhibitor in Untreated Patients (ORLANDO, Dec. 9, 2025) – In a new trial, the Brut...

LBA-2: Primary results from VAYHIT2, a randomized, double-blind, phase 3 trial of ianalumab plus eltrombopag versus placebo plus eltrombopag in patients with primary immune thrombocytopenia (ITP) who failed first-line corticosteroid treatment (ORLAND...

Chemotherapy-free approaches could offer comparable efficacy with less toxicity (ORLANDO, Dec. 7, 2025) — Targeted therapies and immunotherapies are increasingly offering viable alternatives to the chemotherapies that have stood for decades as...

Emerging tests and treatment strategies guide more tailored approaches and ease the burden on patients (ORLANDO, Dec. 6, 2025) — Four clinical trials to be presented at the 67th American Society of Hematology (ASH) Annual Meeting and Expositio...

Although condition is very treatable, less than half of patients receive chelation (ORLANDO – December 6, 2025) — New research presented at the 2025 American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, Florida,...

New research re-examines existing practices, identifies gaps and unmet needs (ORLANDO, Dec. 6, 2025) –– Four studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition spotlight how re-examining exis...

With an emphasis on real-world data, studies guide application of both longstanding and emerging therapies (ORLANDO, Dec. 6, 2025) — Five studies presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition reveal n...

Leaders honored for their work in enhancing patient care and supporting research (WASHINGTON – Nov. 25, 2025) — The American Society of Hematology (ASH) will honor U.S. Senators Susan Collins (R-ME), Patty Murray (D-WA), Shelley Moore Capito (R-WV),...